News
8 April, 2024 - 13:00 (CEST)
M
New Invitation for Expression of Interest (EOI) to manufacturers of medicinal products for treatment of neglected tropical diseases published
Addition:
Under section: Single ingredient medicines to treat lymphatic filariasis, soil-transmitted helminthiasis (STH), and schistosomiasis, taeniasis, cutaneous leishmaniasis, visceral leishmaniasis, yaws disease, scabies, leprosy and Human African trypanosomiasis (HAT)
- Arpraziquantel 150mg and 300mg (scored) dispersible tablet; preferably orodispersible tablet (also known as L-praziquantel or R-(-)-praziquantel)
- Rifampicin 150mg and 300mg capsules (This product is also invited by WHO for treatment of tuberculosis, see EOI for FPPs for tuberculosis.)